Vincerx Pharma Inc (VINC NASDAQ) stock market data APIs
$0.2315
-0(-0%)
as of January 2, 2025
Vincerx Pharma Inc Financial Data Overview
Price chart is built with
Anychart
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
Prev. Close
0.2353
Open
0.2315
Volume
7 234 K
High
0.252
Low
0.2002
52 wk Range
0.1754-9.3722
Market Cap
10 481 K
Shares Outstanding
30 881 K
Revenue
0
EPS
-0.1717
Beta
1.267
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Vincerx Pharma Inc data using free add-ons & libraries
Get Vincerx Pharma Inc Fundamental Data
Vincerx Pharma Inc Fundamental data includes:
- Net Revenue: 0
- EBITDA: -29 934 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-12
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Vincerx Pharma Inc News
New
15 Best Falling Stocks To Buy Now
In this article, we will take a detailed look at the15 Best Falling Stocks To Buy Now. For a quick overview of such stocks, read our article 5Best Falling Stocks To Buy Now. The Wall Street is heade...
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2nd cohort Phase 1 dos...
Vincerx Pharma To Present Three Posters at ASH 2023 in December
VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enit...
New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Network
NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) -- New to The Street, an FMW Media business show production, will air its corporate interviews, episodes 521 and 522, as Sponsored Programming on Bloomberg T...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- 100 000+ API requests per day
- EOD Data - All World Extended
- Splits and Dividends
- Fundamental Data
- Bonds Data
- Options Data
- 1000+ currency pairs
- 1000+ cryptocurrency pairs
